We are live on ! Find out more
CCCC icon

C4 Therapeutics
CCCC

83 hedge funds and large institutions have $927M invested in C4 Therapeutics in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 10

33% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 21

25% more capital invested

Capital invested by funds: $743M → $927M (+$183M)

17% more funds holding in top 10

Funds holding in top 10: 6 → 7 (+1)

11% more funds holding

Funds holding: 75 → 83 (+8)

5.43% more ownership

Funds ownership: 52.77% → 58.2% (+5.4%)

Holders
83
Holders Change
+8
Holders Change %
+10.67%
% of All Funds
1.46%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.12%
New
18
Increased
28
Reduced
21
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WA
Wasatch Advisors
Utah
+$43.2M
2
State Street
State Street
Massachusetts
+$27.8M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$22.6M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
+$12.7M
5
Jennison Associates
Jennison Associates
New York
+$12.6M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$14.9M
2
LGM
Logos Global Management
California
-$14.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.2M
4
SCM
Suvretta Capital Management
New York
-$4.75M
5
ACM
Asymmetry Capital Management
California
-$4.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
MS
26
Mizuho Securities
Japan
$6.27M – – –
DGM
27
Darwin Global Management
Jersey
$5.18M -$3.52M -88,561 -39%
Northern Trust
28
Northern Trust
Illinois
$4.41M -$238K -5,994 -5%
LGM
29
Logos Global Management
California
$4.18M -$14.5M -365,000 -76%
IC
30
Ikarian Capital
Texas
$4.12M -$1.59M -40,000 -26%
N
31
Nuveen
North Carolina
$3.82M +$3.13M +78,690 +320%
MS
32
Maven Securities
Jersey
$2.73M -$1.06M -26,692 -26%
Charles Schwab
33
Charles Schwab
California
$2.58M +$118K +2,970 +4%
TD Asset Management
34
TD Asset Management
Ontario, Canada
$2.46M +$2.02M +50,772 +322%
Citigroup
35
Citigroup
New York
$2.13M +$2.21M +55,584 +2,752%
WP
36
Woodline Partners
California
$2.04M -$4.43M -111,299 -67%
PAWC
37
P.A.W. Capital
Connecticut
$1.85M +$398K +10,000 +25%
Bank of America
38
Bank of America
North Carolina
$1.8M +$1.7M +42,644 +696%
Rafferty Asset Management
39
Rafferty Asset Management
New York
$1.74M +$1.87M +46,906 New
Ensign Peak Advisors
40
Ensign Peak Advisors
Utah
$1.48M – – –
Federated Hermes
41
Federated Hermes
Pennsylvania
$1.44M +$1.55M +38,975 New
Ohio Public Employees Retirement System (OPERS)
42
Ohio Public Employees Retirement System (OPERS)
Ohio
$1.37M +$1.48M +37,122 New
Bank Julius Baer & Co
43
Bank Julius Baer & Co
Switzerland
$1.25M +$1.35M +33,905 New
Bank of New York Mellon
44
Bank of New York Mellon
New York
$1.09M +$46.8K +1,176 +4%
Prudential Financial
45
Prudential Financial
New Jersey
$879K +$944K +23,740 New
PPA
46
Parametric Portfolio Associates
Washington
$818K +$315K +7,916 +56%
Morgan Stanley
47
Morgan Stanley
New York
$784K +$481K +12,087 +133%
Citadel Advisors
48
Citadel Advisors
Florida
$749K -$3.33M -83,622 -81%
AAA
49
Affinity Asset Advisors
New York
$740K – – –
Vontobel Holding
50
Vontobel Holding
Switzerland
$740K – – –
1
2
3 4

CCCC Hedge Fund Activity: Q1 2021 in Review

83 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q1 2021, worth a combined $927M — up 25% from $743M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CCCC positions and 10 closed out — a net gain of 8 holders — while 28 added to existing stakes and 21 trimmed.

The largest buyer was Wasatch Advisors, opening a new position worth an estimated $43.2M. The largest seller was Millennium Management, cutting an estimated $14.9M.

  • 83 institutional investors held C4 Therapeutics (CCCC) as of Q1 2021, up from 75 in Q4 2020.
  • Funds reported $927M of C4 Therapeutics stock for Q1 2021, up 25% quarter-over-quarter.
  • 18 funds opened new C4 Therapeutics positions in Q1 2021 and 10 closed out, a net change of +8 holders.
  • The largest C4 Therapeutics buyer in Q1 2021 was Wasatch Advisors, an estimated $43.2M added.
  • The largest C4 Therapeutics seller in Q1 2021 was Millennium Management, an estimated $14.9M sold.

Based on aggregated 13F filings for Q1 2021.